Requirement for ergosterol in V-ATPase function underlies antifungal activity of azole drugs.
Ergosterol is an important constituent of fungal membranes. Azoles inhibit ergosterol biosynthesis, although the cellular basis for their antifungal activity is not understood. We used multiple approaches to demonstrate a critical requirement for ergosterol in vacuolar H(+)-ATPase function, which is known to be essential for fungal virulence. Ergosterol biosynthesis mutants of S. cerevisiae failed to acidify the vacuole and exhibited multiple vma(-) phenotypes. Extraction of ergosterol from vacuolar membranes also inactivated V-ATPase without disrupting membrane association of its subdomains. In both S. cerevisiae and the fungal pathogen C. albicans, fluconazole impaired vacuolar acidification, whereas concomitant ergosterol feeding restored V-ATPase function and cell growth. Furthermore, fluconazole exacerbated cytosolic Ca(2+) and H(+) surges triggered by the antimicrobial agent amiodarone, and impaired Ca(2+) sequestration in purified vacuolar vesicles. These findings provide a mechanistic basis for the synergy between azoles and amiodarone observed in vitro. Moreover, we show the clinical potential of this synergy in treatment of systemic fungal infections using a murine model of Candidiasis. In summary, we demonstrate a new regulatory component in fungal V-ATPase function, a novel role for ergosterol in vacuolar ion homeostasis, a plausible cellular mechanism for azole toxicity in fungi, and preliminary in vivo evidence for synergism between two antifungal agents. New insights into the cellular basis of azole toxicity in fungi may broaden therapeutic regimens for patient populations afflicted with systemic fungal infections.
The Johns Hopkins University School of Medicine of Baltimore, Maryland, United States of America.
Yong-Qiang
YQ
Zhang
Soledad
S
Gamarra
Guillermo
G
Garcia-Effron
Steven
S
Park
David S
DS
Perlin
Rajini
R
Rao
D000638:Amiodarone / Q000494:pharmacology; D000818:Animals; D000935:Antifungal Agents / Q000494:pharmacology*; D002176:Candida albicans / Q000187:drug effects* / Q000201:enzymology; D004357:Drug Synergism; D004791:Enzyme Inhibitors / Q000494:pharmacology; D004875:Ergosterol / Q000494:pharmacology*; D005260:Female; D015725:Fluconazole / Q000494:pharmacology; D051379:Mice; D008807:Mice, Inbred BALB C; D011522:Protons; D012441:Saccharomyces cerevisiae / Q000187:drug effects* / Q000201:enzymology; D025262:Vacuolar Proton-Translocating ATPases / Q000037:antagonists & inhibitors / Q000378:metabolism*; D014617:Vacuoles / Q000201:enzymology*
D000935:Antifungal Agents; D004791:Enzyme Inhibitors; D011522:Protons; D015725:Fluconazole; D025262:Vacuolar Proton-Translocating ATPases; D000638:Amiodarone; D004875:Ergosterol